Cargando…
Mavacamten has a differential impact on force generation in myofibrils from rabbit psoas and human cardiac muscle
Mavacamten (MYK-461) is a small-molecule allosteric inhibitor of sarcomeric myosins being used in preclinical/clinical trials for hypertrophic cardiomyopathy treatment. A better understanding of its impact on force generation in intact or skinned striated muscle preparations, especially for human ca...
Autores principales: | Scellini, Beatrice, Piroddi, Nicoletta, Dente, Marica, Vitale, Giulia, Pioner, Josè Manuel, Coppini, Raffaele, Ferrantini, Cecilia, Poggesi, Corrado, Tesi, Chiara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077167/ https://www.ncbi.nlm.nih.gov/pubmed/33891673 http://dx.doi.org/10.1085/jgp.202012789 |
Ejemplares similares
-
A Novel Method of Isolating Myofibrils From Primary Cardiomyocyte Culture Suitable for Myofibril Mechanical Study
por: Woulfe, Kathleen C., et al.
Publicado: (2019) -
The relation between sarcomere energetics and the rate of isometric tension relaxation in healthy and diseased cardiac muscle
por: Vitale, Giulia, et al.
Publicado: (2019) -
Genotype-Driven Pathogenesis of Atrial Fibrillation in Hypertrophic Cardiomyopathy: The Case of Different TNNT2 Mutations
por: Pioner, Josè Manuel, et al.
Publicado: (2022) -
R4496C RyR2 mutation impairs atrial and ventricular contractility
por: Ferrantini, Cecilia, et al.
Publicado: (2016) -
T-tubule remodeling in human hypertrophic cardiomyopathy
por: Vitale, Giulia, et al.
Publicado: (2020)